Impact of RANGAP1 SUMOylation on Smad4 nuclear export by bioinformatic analysis and cell assays
Biomolecules and Biomedicine · 2024
DOI: 10.17305/bb.2024.10443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2024. Verfasst von Feng Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Sumoylation, Computational Biology, Cell Proliferation, Smad4 Protein. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Small Ubiquitin-like Modifier (SUMOylation) regulates a variety of cellular activities, and its dysregulation has been associated with glioma etiology. The aim of this research was to clarify the function of SUMOylation-related genes in glioma and determine relevant prognostic markers. The Cancer Genome Atlas (TCGA) Glioma and GSE16011 datasets were analyzed through bioinformatics to identify Ran GTPase activating protein 1 (RANGAP1) as the hub gene for further study. Experimental validation consisted of quantitative real-time polymerase chain reaction (qRT-PCR), western blotting (WB), and immunoprecipitation (IP) to evaluate RANGAP1 expression, function, and interaction with SUMO1. To assess the role of RANGAP1 knockdown and SUMOylation in glioma cells, various assays were conducted, including cell proliferation, migration, invasion, and apoptosis. In addition, cell cycle analysis and immunofluorescence were performed. Through bioinformatics, RANGAP1 was identified as a crucial prognostic gene for glioma. Experimental studies confirmed the downregulation of RANGAP1 in glioma cells and verified that RANGAP1 repair impedes tumor growth. When it comes to RANGAP1 silencing, it enhanced cell proliferation, invasion and migration. Additionally, SUMO1 was identified as a specific SUMO molecule coupled to RANGAP1, affecting the location of Sma and Mad related protein 4 (Smad4) in the nucleocytoplasm and the transforming growth factor (TGF)-β/Smad signaling pathway. The functional impact of RANGAP1 SUMOylation on cell proliferation and migration was further confirmed through experiments using a SUMOylation-impairing mutation (K524R). Our findings suggest that RANGAP1 may be a potential prognostic marker in gliomas and could play a role in regulating cell proliferation, migration, and invasion. SUMOylation of RANGAP1 is responsible for regulating the TGF-β/Smad signaling pathway, which is crucial for the progression of tumors. Further investigations and experiments are necessary to confirm these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Anesthesiology, Huashan Hospital, Fudan University, Shanghai, China.
Zitieren
APA
Zhang, F., Yang, J., & Cheng, Y. (2024). Impact of RANGAP1 SUMOylation on Smad4 nuclear export by bioinformatic analysis and cell assays. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2024.10443
Vancouver
Zhang F, Yang J, Cheng Y. Impact of RANGAP1 SUMOylation on Smad4 nuclear export by bioinformatic analysis and cell assays. Biomolecules and Biomedicine. 2024. doi:10.17305/bb.2024.10443
BibTeX
@article{Zhang2024,
author = {Zhang, Feng and Yang, Jun and Cheng, Yifei},
title = {Impact of RANGAP1 SUMOylation on Smad4 nuclear export by bioinformatic analysis and cell assays},
journal = {Biomolecules and Biomedicine},
year = {2024},
doi = {10.17305/bb.2024.10443}
}
EUVIMED